Breaking News Instant updates and real-time market news.

AMRN

Amarin

$17.25

-0.42 (-2.38%)

10:40
04/18/19
04/18
10:40
04/18/19
10:40

Opening put buyer in Amarin selects strike 32% below spot

Opening put buyer in Amarin selects strike 32% below spot. Customer on NYSE-Arca paid 10c for 2K May 12 puts as shares traded $17.78 early in the session. Shares are up nearly $4 YTD, and the position will capture earnings in early May.

  • 24

    Apr

  • 06

    May

AMRN Amarin
$17.25

-0.42 (-2.38%)

03/21/19
STFL
03/21/19
INITIATION
Target $27
STFL
Buy
Amarin initiated with a Buy at Stifel
Stifel analyst Derek Archila started Amarin with a Buy rating and $27 price target.
03/21/19
STFL
03/21/19
INITIATION
Target $27
STFL
Buy
Stifel starts Amarin with Buy rating, sees 'robust' growth for Vascepa
Stifel analyst Derek Archila initiated coverage of Amarin with a Buy rating and $27 price target. The shares closed the trading day down 25c to $18.76 but are trading up $1.08 to $19.84 in the after-hours market. Vascepa's Reduce-IT study results are "impressive" and a physician survey shows they will "most certainly lead to robust growth," likely above management's 2019 guidance, Archila tells investors in a research note. The analyst adds, though, that his call "runs counter to the prevailing sentiment" that Amarin will be acquired in the near term. He believes the outcome of an FDA advisory committee discussing the Reduce-IT results and controversies around them will be needed before a takeout can occur. Nonetheless, his due diligence with regulatory experts get him comfortable with an FDA approval for a Vascepa label expansion to include reduction in cardiovascular risk based on the Reduce-IT results in early 2020. This should effectively increase the drug's addressable market size by a factor of 20, says Archila. The analyst used a "blended methodology given the takeout premium in the stock" to arrive at a $27 target price.
03/28/19
JEFF
03/28/19
NO CHANGE
Target $30
JEFF
Buy
ADA addition should help drive Vascepa sales in 2019, says Jefferies
The American Diabetes Association updated its treatment guidelines to include Amarin's Vascepa for patients with diabetes and cardiovascular disease, Jefferies analyst Michael Yee tells investors in a research note. The analyst views the addition as an incremental positive that should help drive Vascepa sales in 2019. Further, Q1 scripts suggest Vascepa sales of $80M-$85M, above the consensus estimate of $67M, Yee says. He keeps a Buy rating on Amarin with a $30 price target.
03/28/19
STFL
03/28/19
NO CHANGE
STFL
Buy
ADA endorsement a 'big score' for Amarin's Vascepa, says Stifel
After the American Diabetes Association updated its Standards of Medical Care to include a recommendation that Vascepa be considered for certain patients with diabetes, Stifel analyst Derek Archila called the news a "big score" for Vascepa and a significant endorsement of Vascepa's REDUCE-IT data. The analyst, who continues to view Amarin's 2019 Vascepa sales guidance as beatable, keeps a Buy rating on Amarin shares.

TODAY'S FREE FLY STORIES

BHVN

Biohaven Pharmaceutical

$53.79

-0.235 (-0.44%)

07:32
12/06/19
12/06
07:32
12/06/19
07:32
Hot Stocks
Biohaven's troriluzole successfully advances past interim futility analysis »

Biohaven announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAGE

Sage Therapeutics

$60.11

-89.11 (-59.72%)

07:30
12/06/19
12/06
07:30
12/06/19
07:30
Recommendations
Sage Therapeutics analyst commentary  »

Sage Therapeutics price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRIS

Curis

$1.86

0.045 (2.48%)

07:29
12/06/19
12/06
07:29
12/06/19
07:29
Hot Stocks
Curis provides updated results from Phase 1 dose escalation study of CA-4948 »

Curis announced updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

XNCR

Xencor

$40.63

0.05 (0.12%)

07:29
12/06/19
12/06
07:29
12/06/19
07:29
Conference/Events
Xencor to host analyst & investor meeting »

Analyst & Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

MRVL

Marvell

$23.44

-0.48 (-2.01%)

07:27
12/06/19
12/06
07:27
12/06/19
07:27
Recommendations
Marvell analyst commentary  »

Marvell price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 06

    Jan

SON

Sonoco

$59.91

-0.04 (-0.07%)

07:25
12/06/19
12/06
07:25
12/06/19
07:25
Conference/Events
Sonoco to host investor meeting »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 09

    Dec

  • 13

    Dec

RRC

Range Resources

$3.59

0.01 (0.28%)

07:23
12/06/19
12/06
07:23
12/06/19
07:23
Downgrade
Range Resources rating change  »

Range Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MR

Montage Resources

$5.30

0.09 (1.73%)

07:22
12/06/19
12/06
07:22
12/06/19
07:22
Upgrade
Montage Resources rating change  »

Montage Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

TGTX

TG Therapeutics

$7.68

-0.51 (-6.23%)

07:19
12/06/19
12/06
07:19
12/06/19
07:19
Conference/Events
TG Therapeutics to host investor & analyst meeting »

Investor & Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

SAGE

Sage Therapeutics

$60.11

-89.11 (-59.72%)

07:15
12/06/19
12/06
07:15
12/06/19
07:15
Downgrade
Sage Therapeutics rating change  »

Sage Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AQST

Aquestive Therapeutics

$8.36

-0.42 (-4.78%)

07:15
12/06/19
12/06
07:15
12/06/19
07:15
Conference/Events
Aquestive Therapeutics to host investor & analyst meeting »

Investor & Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

PHG

Philips

07:13
12/06/19
12/06
07:13
12/06/19
07:13
Upgrade
Philips rating change  »

Morgan Stanley upgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OKTA

Okta

$119.18

-2.64 (-2.17%)

07:13
12/06/19
12/06
07:13
12/06/19
07:13
Recommendations
Okta analyst commentary  »

Okta price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

SAGE

Sage Therapeutics

$60.11

-89.11 (-59.72%)

07:10
12/06/19
12/06
07:10
12/06/19
07:10
Recommendations
Sage Therapeutics analyst commentary  »

Sage Therapeutics price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNST

Constellation Pharmaceuticals

$42.66

-3.34 (-7.26%)

07:08
12/06/19
12/06
07:08
12/06/19
07:08
Conference/Events
Constellation Pharmaceuticals to host investor meeting »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

PBYI

Puma Biotechnology

$7.43

-1.52 (-16.98%)

07:07
12/06/19
12/06
07:07
12/06/19
07:07
Initiation
Puma Biotechnology initiated  »

Puma Biotechnology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGM

MGM Resorts

$31.94

0.17 (0.54%)

07:06
12/06/19
12/06
07:06
12/06/19
07:06
Initiation
MGM Resorts initiated  »

MGM Resorts initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OKTA

Okta

$119.18

-2.64 (-2.17%)

07:05
12/06/19
12/06
07:05
12/06/19
07:05
Recommendations
Okta analyst commentary  »

Okta traction in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

RCKT

Rocket Pharmaceuticals

$19.76

0.54 (2.81%)

07:05
12/06/19
12/06
07:05
12/06/19
07:05
Hot Stocks
Rocket Pharmaceuticals announces first patient treated in Phase 2 RP-L102 study »

Rocket Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

UCBJY

UCB

$0.00

(0.00%)

07:05
12/06/19
12/06
07:05
12/06/19
07:05
Hot Stocks
UCB: Phase 3 BE SURE results met co-primary, ranked secondary endpoints »

UCB announced positive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLG

SL Green Realty

$85.75

-0.08 (-0.09%)

07:05
12/06/19
12/06
07:05
12/06/19
07:05
Conference/Events
SL Green Realty to host investor meeting »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

TELA

Tela Bio

$12.11

-1.09 (-8.26%)

07:04
12/06/19
12/06
07:04
12/06/19
07:04
Hot Stocks
Tela Bio awarded contract with HealthTrust Purchasing Group »

TELA Bio announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ULTA

Ulta Beauty

$236.09

-3.27 (-1.37%)

07:03
12/06/19
12/06
07:03
12/06/19
07:03
Recommendations
Ulta Beauty analyst commentary  »

Ulta Beauty results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Mar

APLT

Applied Therapeutics

$21.78

-2.56 (-10.52%)

07:02
12/06/19
12/06
07:02
12/06/19
07:02
Hot Stocks
Applied Therapeutics to present pre-clinical data highlighting AT-001 »

Applied Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDR

McDermott

$0.81

-0.0175 (-2.10%)

07:02
12/06/19
12/06
07:02
12/06/19
07:02
Hot Stocks
McDermott, Chiyoda, Zachry Group announce first liquid from Freeport LNG Train 2 »

McDermott with its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.